Title
Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Relevance of the Interaction Between Antihypertensive and Antirheumatic Drugs in a Family Practice
Phase
Phase 4Lead Sponsor
University of SplitStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
HypertensionIntervention/Treatment
ibuprofen acetaminophen piroxicam ...Study Participants
88NSAIDs may increase blood pressure and blunt the effects of many antihypertensives. Members of these drug classes differ in their propensity to such an interaction.
To compare prospectively the effects of piroxicam, ibuprofen and acetaminophen on blood pressure control in hypertensive patients with osteoarthritis.
acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
Hypertensive persons taking either lisinopril/hydrochlorothiazide fixed combination or amlodipine all the time.
Intervention: NSAID. Hypertensives with osteoarthritis taking already amlodipine (5-10 mg o.d. per os) were randomized to the following drug interventions: to take either acetaminophen (1000 mg t.i.d. per os), piroxicam (10-20 mg o.d. per os) or ibuprofen (400-600 mg t.i.d. per os) for 1 month
Hypertensives with osteoarthritis taking already lisinopril/hydrochlorothiazide (20/12.5 mg o.d. per os), were sequentially randomized to the following drug interventions: acetaminophen (1000 mg t.i.d.), ibuprofen (400-600 mg t.i.d.) or piroxicam (10-20 mg o.d.), for 1 month each
Inclusion Criteria: Treated hypertensives of either gender aged between 55 and 76 years About 50% with concomitant osteoarthritis of the hip or knee Exclusion Criteria: Normotensive persons or untreated hypertensives Individuals outside the age limits General exclusion criteria (e.g. uncooperative persons, advanced malignancies, participants in other studies)